An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use
Mental Health Clinician · 01.10.2022 · 12 (5) · 270-281
DOI: 10.9740/mhc.2022.10.270 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mental Health Clinician, online erschienen am 03.11.2022. Verfasst von Amy M VandenBerg. Beteiligte Einrichtung: Clinical Associate Professor, University of Michigan College of Pharmacy, Ann Arbor, Michigan, amberg@med.umich.edu. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
There are now 9 available FDA-approved second-generation long-acting injectable antipsychotics including aripiprazole (3), olanzapine (1), paliperidone (3), and risperidone (2). These high-cost medications are commonly used with the goal of improving adherence and patient outcomes. With almost 2 decades of use, key aspects have been well studied, including population pharmacokinetics, CYP interactions and various clinical and economic outcomes. However, there are still unknowns with these medications. Issues including adherence, transition from oral antipsychotics, renal dosing, pharmacogenomics, and managing missed doses will be addressed in the context of 4 patient cases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Associate Professor, University of Michigan College of Pharmacy, Ann Arbor, Michigan, amberg@med.umich.edu.
ORCID-Profile: Amy M VandenBerg
Zitieren
APA
VandenBerg, A. M. (2022). An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use. Mental Health Clinician, 12(5), 270-281. https://doi.org/10.9740/mhc.2022.10.270
Vancouver
VandenBerg AM. An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use. Mental Health Clinician. 2022;12(5):270-281. doi:10.9740/mhc.2022.10.270
BibTeX
@article{VandenBerg2022,
author = {VandenBerg, Amy M},
title = {An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use},
journal = {Mental Health Clinician},
year = {2022},
volume = {12},
number = {5},
pages = {270--281},
doi = {10.9740/mhc.2022.10.270}
}
EUVIMED